glp-1 agonist in esrd Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk Patients With Type 2 Diabetes GLP-1 RECEPTORS AGONISTS Comparisons among
Description
S2: Peptide Hormones and Growth Factors - New EPO Mimetic Pegmolesatide was added as a new erythropoietin (EPO) mimetic agent
82 The direct impact of GLP-1RAs on significant renal outcomes remains uncertain
The drugs are expensive about $1,000 to $1,500 per month
Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5
When the INN is not known, the International Union of Pure and Applied Chemistry (IUPAC) nomenclature is used, accompanied in some cases by the commonly-used name
Svendsen B, Holst JJ
